224 related articles for article (PubMed ID: 16045861)
1. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(4):221-3. PubMed ID: 16045861
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of ultra-Rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma.
Gammeri E; Arena A; D'Anneo R; La Grutta S
Allergol Immunopathol (Madr); 2005; 33(3):142-4. PubMed ID: 15946626
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of feasibility of ultra-rush (20-25 minutes) sublingual-swallow immunotherapy in 679 patients (699 sessions) with allergic rhinitis and/or asthma.
Rossi RE; Monasterolo G
Int J Immunopathol Pharmacol; 2005; 18(2):277-85. PubMed ID: 15888250
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children.
Tripodi S; Di Rienzo Businco A; Benincori N; Scala G; Pingitore G
Int Arch Allergy Immunol; 2006; 139(2):149-52. PubMed ID: 16374025
[TBL] [Abstract][Full Text] [Related]
5. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
6. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
Esch RE; Bush RK; Peden D; Lockey RF
Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase.
Giordano T; Quarta C; Bruno ME; Falagiani P; Riva G
Eur Ann Allergy Clin Immunol; 2006 Nov; 38(9):310-2. PubMed ID: 17191751
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety and tolerability of sublingual monomeric allergoid in tablets given without up-dosing to pediatric patients with allergic rhinitis and/or asthma due to grass pollen.
Agostinis F; Foglia C; Bruno ME; Falagiani P
Eur Ann Allergy Clin Immunol; 2009 Dec; 41(6):177-80. PubMed ID: 20128231
[TBL] [Abstract][Full Text] [Related]
9. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy.
Rodríguez-Pérez N; Ambriz-Moreno Mde J; Canonica GW; Penagos M
Ann Allergy Asthma Immunol; 2008 Sep; 101(3):304-10. PubMed ID: 18814454
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
Bahceciler NN; Cobanoglu N
Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
[TBL] [Abstract][Full Text] [Related]
11. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.
Wang DH; Chen L; Cheng L; Li KN; Yuan H; Lu JH; Li H
Laryngoscope; 2013 Jun; 123(6):1334-40. PubMed ID: 23616386
[TBL] [Abstract][Full Text] [Related]
12. [The value and possibilities of immunotherapy in the treatment of allergic rhinitis].
Pfaar O; Hörmann K; Klimek L
MMW Fortschr Med; 2006 Feb; 148(5):28-32. PubMed ID: 16518935
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life.
De Castro G; Zicari AM; Indinnimeo L; Tancredi G; di Coste A; Occasi F; Castagna G; Giancane G; Duse M
Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2225-31. PubMed ID: 23893190
[TBL] [Abstract][Full Text] [Related]
14. Practice parameters for sublingual immunotherapy.
Ortolani C; Agostinis F; Amoroso S; Ariano R; Barbato A; Bassi M; Cadario G; Campi P; Cardinale F; Ciprandi G; D'Anneo R; Di Gioacchino M; Di Rienzo V; Fiocchi A; Galimberti M; Galli E; Giovannini M; Incorvaia C; La Grutta S; Lombardi C; Marcucci F; Marseglia G; Minelli M; Musarra A; Nettis E; Novembre E; Pajno G; Patriarca G; Pezzuto F; Piras P; Pucci S; Romano A; Romano C; Quercia O; Scala G; Schiavino D; Senna G; Sforza G; Tosca M; Tripodi S; Frati F
Monaldi Arch Chest Dis; 2006 Mar; 65(1):44-6. PubMed ID: 16700194
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability and clinical efficacy of ultra-rush sublingual immunotherapy among patients suffering from allergic rhinitis.
Balaji R; Parasuramalu BG; Chandregowda BV; Gangaboraiah
Allergol Immunopathol (Madr); 2014; 42(3):216-23. PubMed ID: 23481554
[TBL] [Abstract][Full Text] [Related]
16. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis.
Wilson DR; Lima MT; Durham SR
Allergy; 2005 Jan; 60(1):4-12. PubMed ID: 15575924
[TBL] [Abstract][Full Text] [Related]
17. Safety of ultra-rush titration of sublingual immunotherapy in asthmatic children with tree-pollen allergy.
Mösges R; Graute V; Christ H; Sieber HJ; Wahn U; Niggemann B
Pediatr Allergy Immunol; 2010 Dec; 21(8):1135-8. PubMed ID: 21121080
[TBL] [Abstract][Full Text] [Related]
18. Sublingual immunotherapy for allergic rhinitis.
Wilson DR; Torres LI; Durham SR
Cochrane Database Syst Rev; 2003; (2):CD002893. PubMed ID: 12804442
[TBL] [Abstract][Full Text] [Related]
19. One century of allergen-specific immunotherapy for respiratory allergy.
Incorvaia C; Frati F
Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents.
Seidenberg J; Pajno GB; Bauer CP; La Grutta S; Sieber J
J Investig Allergol Clin Immunol; 2009; 19(2):125-31. PubMed ID: 19476016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
